LON:INDV Indivior (INDV) Share Price, News & Analysis GBX 1,238 +19.00 (+1.56%) As of 07/24/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesBuy This Stock About Indivior Stock (LON:INDV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Indivior alerts:Sign Up Key Stats Today's Range 1,230▼ 1,26450-Day Range 844.58▼ 1,23852-Week Range 548.71▼ 1,264Volume8.46 million shsAverage Volume798,658 shsMarket Capitalization£1.93 billionP/E RatioN/ADividend Yield1.21%Price TargetGBX 1,650Consensus RatingBuy Company Overview Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. Read More Indivior Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreINDV MarketRank™: Indivior scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIndivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndivior has received no research coverage in the past 90 days.Read more about Indivior's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is -1,026.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is -1,026.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioDue to a projected decrease in earnings for Indivior, their PEG ratio cannot be calculated. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for INDV. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipIndivior is a leading dividend payer. It pays a dividend yield of 4.48%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthIndivior does not have a long track record of dividend growth.Read more about Indivior's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for INDV. News and Social Media2.4 / 5News Sentiment0.25 News SentimentIndivior has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Indivior this week, compared to 1 article on an average week.Search Interest5 people have searched for INDV on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have bought more of their company's stock than they have sold. Specifically, they have bought £80,157 in company stock and sold GBX 0 in company stock.Percentage Held by InsidersOnly 3.44% of the stock of Indivior is held by insiders.Percentage Held by Institutions85.98% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Indivior's insider trading history. Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address INDV Stock News HeadlinesIndivior PLC: Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial GuidanceJuly 31 at 12:49 AM | finanznachrichten.deIndivior PLC (INDV) Reinvents Leadership, Moves Listing to NasdaqJuly 28, 2025 | msn.comMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alternative Assets reveals 3 urgent moves to protect your portfolio, plus the #1 asset class thriving during crises (hint: it’s not stocks or bonds). | American Alternative (Ad)Indivior drops London listing to focus on U.S. marketJune 2, 2025 | investing.comWall Street Breakfast Podcast: Steel Surges On Tariff HikeJune 2, 2025 | seekingalpha.comIndivior to Cancel London Listing; Nasdaq to Remain Primary ListingJune 2, 2025 | marketwatch.comIndivior to delist from London Stock Exchange, maintain Nasdaq listingJune 2, 2025 | reuters.comIndivior Announces Patrick Barry as Chief Commercial OfficerMay 27, 2025 | finance.yahoo.comSee More Headlines INDV Stock Analysis - Frequently Asked Questions How have INDV shares performed this year? Indivior's stock was trading at GBX 1,024 on January 1st, 2025. Since then, INDV stock has increased by 20.9% and is now trading at GBX 1,238. How do I buy shares of Indivior? Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some other companies that Indivior investors own include Futura Medical (FUM), Bigblu Broadband (BBB), Directa Plus (DCTA), Lakehouse (LAKE), Kingfisher (KGF), Sirius XM (SIRI) and Aquila Services Group (AQSG). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolLON:INDV CIKN/A Webindivior.com Phone+44-1753-217800FaxN/AEmployees1,000Year FoundedN/APrice Target and Rating Average Price Target for IndiviorGBX 1,650 High Price TargetGBX 1,800 Low Price TargetGBX 1,500 Potential Upside/Downside+33.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)GBX (1.21) Trailing P/E RatioN/A Forward P/E Ratio1,167.92 P/E Growth-5.57Net Income-£2.36 million Net Margins-0.17% Pretax MarginN/A Return on Equity-0.77% Return on Assets2.37% Debt Debt-to-Equity Ratio-170.06 Current Ratio0.83 Quick Ratio1.52 Sales & Book Value Annual Sales£1.40 billion Price / Sales1.38 Cash FlowGBX 461.92 per share Price / Cash Flow2.68 Book ValueGBX (126.42) per share Price / Book-9.79Miscellaneous Outstanding Shares156,209,528Free FloatN/AMarket Cap£1.93 billion OptionableNot Optionable Beta0.19 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (LON:INDV) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.